Amicus Therapeutics (FOLD) 8.15 $FOLD
Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease
GlobeNewswire - Thu Dec 11, 6:30AM CST
Successful Pre-Submission Meeting with European Medicines Agency Completed
FOLD: 8.15 (+0.18)
Amicus Therapeutics Has Returned 30.9% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Dec 10, 9:12AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 3 weeks, Amicus Therapeutics has returned 30.92% as of today's recent price of $8.72.
FOLD: 8.15 (+0.18)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Amicus Therapeutics to Present at Oppenheimer Healthcare Conference
GlobeNewswire - Thu Dec 04, 3:04PM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the 25th Annual Oppenheimer Healthcare Conference in New York, NY on Thursday, December 11, 2014 at 1:35 p.m. ET.
FOLD: 8.15 (+0.18)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 62.32 (+0.45), OPK: 8.18 (-0.11), ISR: 1.62 (-0.02), FOLD: 8.15 (+0.18), NSPH: 0.36 (+0.02)
Fabry Disease - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/sgtssl/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fabry Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amicus Therapeutics - Biosidus - Genzyme Corporation - greenovation Biotech GmbH - iBio - ISU ABXIS - JCR Pharmaceuticals - Neuraltus Pharmaceuticals - Pharming Group - Protalix BioTherapeutics For more information visit http://www.researchandmarkets.com/research/sg...ry_disease
FOLD: 8.15 (+0.18)
16.2% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Tue Dec 02, 5:03PM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 2 weeks, Amicus Therapeutics has returned 16.22% as of today's recent price of $7.74.
FOLD: 8.15 (+0.18)
Will Amicus Therapeutics (FOLD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:41AM CST
Will Amicus Therapeutics (FOLD) Continue to Surge Higher?
FOLD: 8.15 (+0.18)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 8.44 (+0.22), KNMD: (), OPK: 8.18 (-0.11), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18), NVS: 93.52 (-0.82)
Amicus Therapeutics (FOLD) Weak On High Volume
at The Street - Mon Dec 01, 9:00AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a weak on high relative volume candidate
FOLD: 8.15 (+0.18)
Amicus Therapeutics anticipates gross proceeds of USD103.5m from public offering, including underwriters option
M2 - Wed Nov 26, 6:59AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) said on Tuesday that it has closed its public offering, including the underwriters full exercise of their option to purchase an additional 2,077,500 shares.
FOLD: 8.15 (+0.18)
5 Stocks With Big Insider Buying: Hertz Global and More
at The Street - Wed Nov 26, 5:00AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
CJES: 11.64 (-0.43), HTZ: 21.33 (-1.01), STAA: 9.12 (-0.02), JCP: 6.38 (+0.29), FOLD: 8.15 (+0.18)
InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC
InsiderInsights - at Seeking Alpha - Wed Nov 26, 12:20AM CST
SC: 17.65 (-0.71), ACMP: 52.76 (-1.62), NEOT: 7.49 (-0.48), BBY: 36.85 (+0.22), SGM: 11.60 (-0.29), FIVE: 37.39 (+0.24), AVID: 14.28 (-0.20), FCF: 8.61 (-0.13), SPW: 79.82 (-2.48), NLNK: 35.69 (+0.27), AINC: 87.50 (+1.53), PF: 34.46 (-0.23), AAPL: 109.73 (-1.89), SFXE: 3.85 (-0.09), INTU: 92.17 (-1.20), CSCO: 26.85 (-0.14), FOLD: 8.15 (+0.18), KPTI: 34.85 (+1.35)
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
GlobeNewswire - Mon Nov 24, 3:00PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,077,500 shares of common stock. As a result, the Company issued a total of 15,927,500 shares in the offering at a price of $6.50 per share.
JPM: 60.04 (-1.10), FOLD: 8.15 (+0.18)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 39.14 (-1.17), FATE: 3.69 (+0.01), CNDO: 2.18 (-0.11), RCPT: 120.08 (-1.38), FOLD: 8.15 (+0.18)
BioMarin Buys Prosensa Backs Up Troubled Drug
at Investor's Business Daily - Mon Nov 24, 9:22AM CST
Biotech BioMarin Pharmaceutical (BMRN) agreed Monday to pay $680 million in cash for Prosensa Holding, developer of a muscular-dystrophy drug with a checkered history. Prosensa soared 63%, while BioMarin slipped a fraction in early trading in the...
BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), SRPT: 13.97 (-0.33), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18)
Amicus Therapeutics Earnings Hindsight: Up 18.5% in Last 18 Days (FOLD)
Comtex SmarTrend(R) - Mon Nov 24, 8:45AM CST
When Amicus Therapeutics (NASDAQ:FOLD) reported earnings 18 days ago on November 6th, 2014, analysts, on average, expected the company to report a loss of $0.21 on sales of $500.0 thousand. The company actually reported a loss of $0.23 per share on sales of $293.0 thousand, missing EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Amicus Therapeutics have risen from $5.88 to $6.96, representing a gain of 18.5% in the past 18 days.
FOLD: 8.15 (+0.18)
InsiderInsights.com Daily Round Up 11/19/14: CJES, MGPI, PSX, STAA
InsiderInsights - at Seeking Alpha - Thu Nov 20, 1:58AM CST
PSX: 65.68 (-1.14), CJES: 11.64 (-0.43), CPS: 52.55 (-0.88), BAH: 25.52 (-1.21), MRD: 18.08 (+0.39), MGPI: 15.78 (-0.62), GOOG: 518.66 (-9.68), MAS: 24.05 (-0.47), ESPR: 37.48 (-1.00), NOW: 61.25 (-0.10), LNKD: 219.90 (+2.54), SCTY: 50.02 (-0.89), STAA: 9.12 (-0.02), AINC: 87.50 (+1.53), FANG: 52.47 (-0.64), SFXE: 3.85 (-0.09), APD: 138.06 (-5.21), CSCO: 26.85 (-0.14), FOLD: 8.15 (+0.18)
Amicus prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:13AM CST
FOLD: 8.15 (+0.18)
Amicus Therapeutics prices offering of common stock at USD6.50 per share
M2 - Wed Nov 19, 5:53AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) revealed on Tuesday that it has priced an offering of 13,850,000 shares of its common stock at USD6.50 per share.
FOLD: 8.15 (+0.18)
Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease
GlobeNewswire - Thu Dec 11, 6:30AM CST
Successful Pre-Submission Meeting with European Medicines Agency Completed
FOLD: 8.15 (+0.18)
Amicus Therapeutics Has Returned 30.9% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Dec 10, 9:12AM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 3 weeks, Amicus Therapeutics has returned 30.92% as of today's recent price of $8.72.
FOLD: 8.15 (+0.18)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Amicus Therapeutics to Present at Oppenheimer Healthcare Conference
GlobeNewswire - Thu Dec 04, 3:04PM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the 25th Annual Oppenheimer Healthcare Conference in New York, NY on Thursday, December 11, 2014 at 1:35 p.m. ET.
FOLD: 8.15 (+0.18)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 62.32 (+0.45), OPK: 8.18 (-0.11), ISR: 1.62 (-0.02), FOLD: 8.15 (+0.18), NSPH: 0.36 (+0.02)
Fabry Disease - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/sgtssl/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fabry Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amicus Therapeutics - Biosidus - Genzyme Corporation - greenovation Biotech GmbH - iBio - ISU ABXIS - JCR Pharmaceuticals - Neuraltus Pharmaceuticals - Pharming Group - Protalix BioTherapeutics For more information visit http://www.researchandmarkets.com/research/sg...ry_disease
FOLD: 8.15 (+0.18)
16.2% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Tue Dec 02, 5:03PM CST
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on November 17th, 2014 at $6.66. In approximately 2 weeks, Amicus Therapeutics has returned 16.22% as of today's recent price of $7.74.
FOLD: 8.15 (+0.18)
Will Amicus Therapeutics (FOLD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 8:41AM CST
Will Amicus Therapeutics (FOLD) Continue to Surge Higher?
FOLD: 8.15 (+0.18)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 8.44 (+0.22), KNMD: (), OPK: 8.18 (-0.11), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18), NVS: 93.52 (-0.82)
Amicus Therapeutics (FOLD) Weak On High Volume
at The Street - Mon Dec 01, 9:00AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a weak on high relative volume candidate
FOLD: 8.15 (+0.18)
Amicus Therapeutics anticipates gross proceeds of USD103.5m from public offering, including underwriters option
M2 - Wed Nov 26, 6:59AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) said on Tuesday that it has closed its public offering, including the underwriters full exercise of their option to purchase an additional 2,077,500 shares.
FOLD: 8.15 (+0.18)
5 Stocks With Big Insider Buying: Hertz Global and More
at The Street - Wed Nov 26, 5:00AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
CJES: 11.64 (-0.43), HTZ: 21.33 (-1.01), STAA: 9.12 (-0.02), JCP: 6.38 (+0.29), FOLD: 8.15 (+0.18)
InsiderInsights.com Daily Round Up 11/25/14: AAPL, FCF, AVID, SC
InsiderInsights - at Seeking Alpha - Wed Nov 26, 12:20AM CST
SC: 17.65 (-0.71), ACMP: 52.76 (-1.62), NEOT: 7.49 (-0.48), BBY: 36.85 (+0.22), SGM: 11.60 (-0.29), FIVE: 37.39 (+0.24), AVID: 14.28 (-0.20), FCF: 8.61 (-0.13), SPW: 79.82 (-2.48), NLNK: 35.69 (+0.27), AINC: 87.50 (+1.53), PF: 34.46 (-0.23), AAPL: 109.73 (-1.89), SFXE: 3.85 (-0.09), INTU: 92.17 (-1.20), CSCO: 26.85 (-0.14), FOLD: 8.15 (+0.18), KPTI: 34.85 (+1.35)
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option
GlobeNewswire - Mon Nov 24, 3:00PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,077,500 shares of common stock. As a result, the Company issued a total of 15,927,500 shares in the offering at a price of $6.50 per share.
JPM: 60.04 (-1.10), FOLD: 8.15 (+0.18)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 39.14 (-1.17), FATE: 3.69 (+0.01), CNDO: 2.18 (-0.11), RCPT: 120.08 (-1.38), FOLD: 8.15 (+0.18)
BioMarin Buys Prosensa Backs Up Troubled Drug
at Investor's Business Daily - Mon Nov 24, 9:22AM CST
Biotech BioMarin Pharmaceutical (BMRN) agreed Monday to pay $680 million in cash for Prosensa Holding, developer of a muscular-dystrophy drug with a checkered history. Prosensa soared 63%, while BioMarin slipped a fraction in early trading in the...
BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), SRPT: 13.97 (-0.33), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18)
Amicus Therapeutics Earnings Hindsight: Up 18.5% in Last 18 Days (FOLD)
Comtex SmarTrend(R) - Mon Nov 24, 8:45AM CST
When Amicus Therapeutics (NASDAQ:FOLD) reported earnings 18 days ago on November 6th, 2014, analysts, on average, expected the company to report a loss of $0.21 on sales of $500.0 thousand. The company actually reported a loss of $0.23 per share on sales of $293.0 thousand, missing EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Amicus Therapeutics have risen from $5.88 to $6.96, representing a gain of 18.5% in the past 18 days.
FOLD: 8.15 (+0.18)
InsiderInsights.com Daily Round Up 11/19/14: CJES, MGPI, PSX, STAA
InsiderInsights - at Seeking Alpha - Thu Nov 20, 1:58AM CST
PSX: 65.68 (-1.14), CJES: 11.64 (-0.43), CPS: 52.55 (-0.88), BAH: 25.52 (-1.21), MRD: 18.08 (+0.39), MGPI: 15.78 (-0.62), GOOG: 518.66 (-9.68), MAS: 24.05 (-0.47), ESPR: 37.48 (-1.00), NOW: 61.25 (-0.10), LNKD: 219.90 (+2.54), SCTY: 50.02 (-0.89), STAA: 9.12 (-0.02), AINC: 87.50 (+1.53), FANG: 52.47 (-0.64), SFXE: 3.85 (-0.09), APD: 138.06 (-5.21), CSCO: 26.85 (-0.14), FOLD: 8.15 (+0.18)
Amicus prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:13AM CST
FOLD: 8.15 (+0.18)
Amicus Therapeutics prices offering of common stock at USD6.50 per share
M2 - Wed Nov 19, 5:53AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) revealed on Tuesday that it has priced an offering of 13,850,000 shares of its common stock at USD6.50 per share.
FOLD: 8.15 (+0.18)
